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ABSTRACT
Background. Data on osteoporosis and fractures in patients
with thyroid cancer, especially men, are conflicting. Our
objective was to determine osteoporosis and fracture risk in
U.S. veterans with thyroid cancer.
Materials and Methods. This is a case-control study using
the Veterans Health Administration Corporate Data Ware-
house (2004–2013). Patients with thyroid cancer (n = 10,370)
and controls (n = 10,370) were matched by age, sex, weight,
and steroid use. Generalized linear mixed-effects regression
model was used to compare the two groups in terms of oste-
oporosis and fracture risk. Next, subgroup analysis of the
patients with thyroid cancer using longitudinal thyroid-
stimulating hormone (TSH) was performed to determine its
effect on risk of osteoporosis and fractures. Other covariates
included patient age, sex, median household income, com-
orbidities, and steroid and androgen use.
Results. Compared with controls, osteoporosis, but not frac-
tures, was more frequent in patients with thyroid cancer
(7.3% vs. 5.3%; odds ratio [OR], 1.33; 95% confidence inter-
val [CI], 1.18–1.49) when controlling for median household
income, Charlson/Deyo comorbidity score, and androgen use.
Subgroup analysis of patients with thyroid cancer demon-
strated that lower TSH (OR, 0.93; 95% CI, 0.90–0.97), female
sex (OR, 4.24; 95% CI, 3.53–5.10), older age (e.g., ≥85 years:
OR, 17.18; 95% CI, 11.12–26.54 compared with <50 years),
and androgen use (OR, 1.63; 95% CI, 1.18–2.23) were associ-
ated with osteoporosis. Serum TSH was not associated with
fractures (OR, 1.01; 95% CI, 0.96–1.07).
Conclusion. Osteoporosis, but not fractures, was more com-
mon in U.S. veterans with thyroid cancer than controls.
Multiple factors may be contributory, with low TSH playing
a small role. The Oncologist 2019;24:1166–1173
Implications for Practice: Data on osteoporosis and fragility fractures in patients with thyroid cancer, especially in men, are
limited and conflicting. Because of excellent survival rates, the number of thyroid cancer survivors is growing and more indi-
viduals may experience long-term effects from the cancer itself and its treatments, such as osteoporosis and fractures. The
present study offers unique insight on the risk for osteoporosis and fractures in a largely male thyroid cancer cohort. Physi-
cians who participate in the long-term care of patients with thyroid cancer should take into consideration a variety of fac-
tors in addition to TSH level when considering risk for osteoporosis.
INTRODUCTION
More than 50,000 Americans are diagnosed with thyroid can-
cer every year [1]. Moreover, survival rates for the majority
of patients with thyroid cancer remain excellent, with more
than 700,000 patients with thyroid cancer currently living in
the U.S. [1]. As the number of thyroid cancer survivors grows,
more individuals may experience long-term health effects
from the cancer itself, as well as from thyroid cancer treat-
ments [1–4]. These health risks include osteoporosis and
fractures.
Thyroid surgery with or without radioactive iodine abla-
tion is the standard of care for patients with thyroid cancer
[5]. In select patients, thyroid-stimulating hormone (TSH)
suppression is also warranted to prevent cancer recurrence
[5]. It has been postulated that TSH suppression therapy,
which induces a state of subclinical hyperthyroidism, may
contribute to bone loss in patients with thyroid cancer, par-
ticularly in postmenopausal women [1]. However, previous
studies exploring the link between thyroid cancer treatment
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and osteoporosis and fractures in men have yielded conflicting
results because of heterogeneity in study design, small sam-
ple sizes, cross-sectional nature, lack of biochemical data,
and varying degrees of control for confounding variables
[1, 6–10].
To address this knowledge gap, we used a largely male
study cohort, the Veterans Health Administration Corporate
Data Warehouse (VHA CDW), to compare osteoporosis and
fracture risks in patients with thyroid cancer versus matched
controls. We subsequently performed a subgroup analysis of
the patients with thyroid cancer using longitudinal TSH to
determine factors associated with osteoporosis and fractures.
MATERIALS AND METHODS
Study Design
This was a retrospective case-control study (1:1 match of
patients with thyroid cancer to controls) using deidentified
national data from the VHA CDW between 2004 and 2013.
A subsequent subgroup analysis of only the patients with
thyroid cancer using longitudinal TSH data was also con-
ducted. This study was exempt from the University of
Michigan Institutional Review Board and approved by the
Ann Arbor Veteran Affairs Institutional Review Board.
Data Source and Study Population
The study population was selected from the VHA CDW
within the Veteran Affairs Informatics and Computing Infra-
structure system. The Veterans Health Administration is the
largest integrated health care system in the country, with
the mission of providing patient-centered, comprehensive
clinical services for veterans [11]. It serves over 9 million
veterans via an extensive network of more than 1,200 facili-
ties in the U.S. [12]. The VHA CDW is a dynamic repository
of patient-level administrative and clinical data, aggregated
from across the VHA’s national health delivery system in
the U.S. [13].
Selection of Cases
We included male and female veterans aged 18 years or
older who had a thyroid cancer diagnosis between
January 1, 2004, and December 31, 2013 (using International
Classification of Diseases [ICD]-9 code 193), who were on thy-
roid hormone replacement therapy (identified as taking
either T4 alone or a T4 plus T3 combination preparation),
and who had at least two outpatient TSH measurements fol-
lowing the date of thyroid cancer diagnosis. We excluded
thyroid function tests measured in the inpatient setting and
in patients at long-term care units, as these patients often
have abnormal thyroid function tests associated with non-
thyroidal illness. Only cases with a complete set of data were
included.
Selection of Controls
Veterans without a diagnosis of thyroid cancer and who were
not on thyroid hormone replacement served as controls. For
each case, we randomly selected one control from multiple
possible matches, matching by sex, age, weight, and steroid
use (1:1 match). Cases and controls were matched by age
according to the date of birth, with dates being within a year
of each other. Weight between cases and controls was mat-
ched within 5 pounds, based on the closest measurement to
the date of thyroid cancer diagnosis or study entry. Only con-
trols with a complete set of data were included.
Covariates
Data collected included information on patient sex, patient
age (categorized as <50, 50–64, 65–74, 75–84, and ≥85 years),
patient weight, median household income (determined by zip
code of residence from the Area Resource File), duration of
steroid use (categorized as none/<3 months versus ≥3
months), androgen use, and comorbidities. Median household
income was included as a measure of socioeconomic status,
which has been shown to be associated with osteoporosis
and fracture risk [14–16]. Steroid and androgen use were
determined using outpatient prescription data. Comorbidities
were determined by the Charlson/Deyo comorbidity score,
which was calculated using the Charlson/Deyo comorbidity
score mapping table (see supplemental online Appendix 1).
This score was categorized as 0, 1, and ≥2. For patients with-
thyroid cancer, serum TSH measurements were gathered
from the patients’ laboratory records and organized into a lon-
gitudinal data set (median TSH, 1.19 mIU/L; range, 0.001–125
mIU/L). The number of serum TSH measurements per patient
ranged between 2 and 111 (median, 14).
Bone Density Scans and Osteoporosis Medications
We captured bone density scans performed following diag-
nosis of thyroid cancer for patients and at time of study entry
for controls. Bone mineral density scans were captured only
if performed prior to diagnosis of osteoporosis and/or frac-
tures. For claims codes used, please see supplemental online
Appendix 1. Additionally, information on medications used to
treat osteoporosis was obtained from outpatient pharmacy
prescriptions for bisphosphonates (alendronate, risedronate,
ibandronate, zoledronic acid), denosumab, teriparatide, and
raloxifene.
Outcome Measures
Patients were identified as having osteoporosis by using ICD-9
codes 733.0x. We used inpatient and outpatient ICD-9 and
Current Procedural Terminology-4 (CPT-4) codes to identify
patients who had at least one fragility fracture during the
study period, including hip, pelvic, vertebral, and forearm/
wrist fractures. Patients with traumatic or pathological frac-
tures were excluded from the analyses. ICD-9 and CPT-4 codes
were entered into the patients’ medical records by their
treating physicians. These deidentified data were obtained
from the Corporate Data Warehouse. For the patients with
thyroid cancer, events of osteoporosis diagnosis and fractures
were only counted if they occurred after the diagnosis of
thyroid cancer (median time to event, 20 months for osteopo-
rosis, 36 months for fractures). For details on the ICD-9
and CPT-4 codes used, refer to the supplemental online
Appendix 1. Data were censored at death or at last follow-up.
Statistical Analysis
First, descriptive statistics were generated for both cases and
controls. Next, generalized linear mixed-effects regression
© AlphaMed Press 2019www.TheOncologist.com
Papaleontiou, Banerjee, Reyes-Gastelum et al. 1167
model based on a logit link was used to identify factors associ-
ated with the risk of osteoporosis and fragility fractures in
cases and controls. Variables included in the regression model
were median household income, Charlson/Deyo comorbidity
index, and androgen use. Matched samples were analyzed as
pairs, and a random intercept was used for the pairs.
Subsequently, we conducted subgroup analyses of patients
with thyroid cancer using separate generalized linear mixed-
effects regression models for osteoporosis and fractures based
on a logit link (n = 10,370). Covariates for these models
included longitudinal TSH, patient age at diagnosis, sex,
median household income, comorbidities, and steroid and
androgen use. Serum TSH was analyzed as a continuous vari-
able and was log transformed prior to analysis because of
nonlinear effect of TSH. Additionally, TSH was used as a time-
varying covariate. This allowed for serial TSH measurements
for each of the observed timepoints during the study period
to be accounted for, incorporating changes to thyroid status
over time in the analyses.
Finally, a subgroup analysis of the patients with thyroid
cancer using longitudinal TSH as a categorical variable was
conducted (TSH categories: <0.1 mIU/L, 0.1–0.5 mIU/L,
0.51–5.5 mIU/L, >5.5 mIU/L), with osteoporosis risk as the
outcome measure. Serum TSH was used as a time-varying
covariate. Serum TSH values in this plot represent model-
predicted cases based on information from the data.
All analyses were conducted using SAS Enterprise Guide
Version 7.15 HF3 (7.100.5.6132; 64-bit; SAS, Cary, NC).
A 95% confidence interval (CI) was used to determine statis-
tical significance. A p value <.05 was considered statistically
significant.
RESULTS
A total of 10,370 patients with thyroid cancer were matched
by age, sex, weight, and steroid use with 10,370 controls dur-
ing the study period of 2004–2013. As shown in Table 1, the
majority of patients were male (83.8%). The median age
was 61 years. Patients with thyroid cancer had more com-
orbidities (28.4% vs. 15.7% with Charlson/Deyo comorbidity
score ≥2) and more androgen use (7.0% vs. 4.2%) than con-
trols. Overall, 882 (8.5%) of patients with thyroid cancer were
on osteoporosis medications, compared with 560 (5.4%) of
controls. Of those with a diagnosis of osteoporosis, a total of
49.6% of patients with thyroid cancer were on an osteoporo-
sis medication versus only 29.6% of controls. Additionally,
23.7% of patients with thyroid cancer underwent bone den-
sity scans compared with 9.7% controls (p < .001) during the
study period.
As demonstrated in Table 2, osteoporosis was more fre-
quent in patients with thyroid cancer compared with mat-
ched controls (7.3% vs 5.3%; odds ratio [OR], 1.33; 95% CI,
1.18–1.49), after controlling for median household income,
Charlson/Deyo comorbidity score, and androgen use.
Table 3 shows that fractures were less common in
patients with thyroid cancer compared with controls (2.4% vs.
2.8%; OR, 0.72; 95% CI, 0.60–0.86), after controlling for
median household income, Charlson/Deyo comorbidity score,
and androgen use. Additionally, when adjusting for diagnosis
of osteoporosis and being on osteoporosis medication(s) in
the multivariable analysis model, it was similarly observed
that there is a lower incidence of fractures in the thyroid can-
cer group compared with matched controls (OR, 0.71; 95% CI,
0.59–0.85).





n (%) Controls, n (%)
Sexa
Male 8,689 (83.8) 8,689 (83.8)
Female 1,681 (16.2) 1,681 (16.2)
Age, yra
<50 2017 (19.4) 2018 (19.5)
50–64 4,539 (43.8) 4,538 (43.8)
65–74 2,267(21.9) 2,265 (21.8)
75–84 1,356 (13.1) 1,357 (13.1)
≥85 191 (1.8) 192 (1.8)
Weighta,b 93.8 (20.1) 93.7 (20.0)
Median household
incomec
<$35,000 1,314 (12.7) 1,412 (13.6)
$35,000–$59,999 6,125 (59.0) 6,387 (61.6)
≥$60,000 2,931 (28.3) 2,571 (24.8)
Charlson/Deyo
comorbidity score
0 6,137 (59.2) 7,802 (75.2)
1 1,284 (12.4) 944 (9.1)
≥2 2,949 (28.4) 1,624 (15.7)
Androgen use
No 9,642 (93.0) 9,935 (95.8)
Yes 728 (7.0) 435 (4.2)
Steroid usea
No or <3 mo 9,144 (88.2) 9,144 (88.2)
≥3 mo 1,226 (11.8) 1,226 (11.8)
Use of osteoporosis
medication
No 9,488 (91.5) 9,810 (94.6)
Yes 882 (8.5) 560 (5.4)
Bone density scans
No 7,911 (76.3) 9,369 (90.3)
Yes 2,459 (23.7) 1,001 (9.7)
Osteoporosisd
No 9,616 (92.7) 9,826 (94.7)
Yes 754 (7.3) 544 (5.3)
Fractures
No 10,117 (97.6) 10,083 (97.2)
Yes 253 (2.4) 287 (2.8)
aCohorts were matched for sex, age according to the date of birth
(matched within 1 year), weight [matched within 5 pounds; reported
in kg as mean (SD)], and steroid use.
bWeight reported in kg as mean (SD).
cMedian household income by geographic region.
dOsteoporosis diagnosed by ICD-9 codes.
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Table 4 demonstrates results from a subsequent subgroup
longitudinal analysis of characteristics associated with osteo-
porosis in patients with thyroid cancer only (n = 10,370), with
serum log transformed TSH analyzed as a continuous variable.
Median follow-up was 52 months. During the study period,
8,493 of 10,370 (82%) patients with thyroid cancer had at
least one serum TSH ≤0.5 mIU/L, which would indicate TSH
suppression. Lower TSH (OR, 0.93; 95% CI, 0.90–0.97), female
sex (OR, 4.24; 95% CI, 3.53–5.10), and androgen use (OR,
1.63; 95% CI, 1.18–2.23) were associated with osteoporosis.
Additionally, older age (e.g., ≥85 years: OR, 17.18; 95% CI,
11.12–26.54, compared with <50 years) was also associated
with osteoporosis in these patients.
Figure 1 illustrates that when analyzing serum TSH as a cat-
egorical variable longitudinally, there were 10.6 osteoporosis
cases per 1,000 patients with thyroid cancer with a serum TSH
<0.1 mIU/L compared with 11.2 cases per 1,000 when TSH
was 0.1–0.5, 8.0 cases per 1,000 when TSH 0.5–5.5 mIU/L, and
7.7 cases per 1,000 when TSH >5.5 mIU/L at any point in time.
For example, in these model-predicted cases, if we take 1,000
patients with their TSH values between 0.1–0.5 mIU/L, we
expect to see 11.2 cases of osteoporosis.
Table 5 shows results from a subgroup analysis of charac-
teristics associated with fractures in patients with thyroid
cancer only (n = 10,370), with longitudinal serum log trans-
formed TSH analyzed as a continuous variable. There was no
significant association between TSH level and risk for frac-
tures (OR, 1.01; 95% CI, 0.96–1.07). However, female sex
(OR, 1.54; 95% CI, 1.07–2.22), older age (e.g., ≥85 years: OR,
9.78; 95% CI, 5.15–18.57; compared with age <50), higher
Table 2. Osteoporosis in patients with thyroid cancer compared with matched controls
Osteoporosis in patients
with thyroid cancer, n (%)
Osteoporosis
in controls,a n (%) OR (95% CI)
Cohortb 754 (7.3) 544 (5.3) 1.33 (1.18–1.49)
Median household incomec
<$35,000 89 (6.8) 69 (4.9) 1.0 (ref)
$35,000–$59,999 440 (7.2) 327 (5.1) 1.07 (0.89–1.29)
≥$60,000 225 (7.7) 148 (5.8) 1.20 (0.97–1.47)
Charlson/Deyo comorbidity score
0 385 (6.3) 332 (4.3) 1.0 (ref)
1 108 (8.4) 62 (6.6) 1.47 (1.22–1.77)
≥2 261 (8.9) 150 (9.2) 1.70 (1.48–1.95)
Androgen use
No 709 (7.3) 526 (5.3) 1.0 (ref)
Yes 45 (6.4) 18 (4.3) 0.84 (0.64–1.11)
aCohorts were matched for sex, age according to the date of birth (matched within 1 year), weight [matched within 5 pounds; reported in kg as
mean (SD)], and steroid use.
bReference group is controls.
cMedian household income by geographic region.
Abbreviations: CI, confidence interval; OR, odds ratio; ref, reference.
Table 3. Fractures in patients with thyroid cancer compared with matched controls
Fractures in patients with
thyroid cancer, n (%)
Fractures in
controls,a n (%) OR (95% CI)
Cohortb 253 (2.4) 287 (2.8) 0.72 (0.60–0.86)
Median household incomec
<$35,000 31 (2.4) 44 (3.1) 1.0 (ref)
$35,000–$59,999 158 (2.6) 172 (2.7) 1.01 (0.77–1.31)
≥$60,000 64 (2.2) 71 (2.8) 0.98 (0.73–1.32)
Charlson/Deyo comorbidity score
0 88 (1.4) 136 (1.7) 1.0 (ref)
1 41 (3.2) 40 (4.2) 2.40 (1.84–3.14)
≥2 124 (4.2) 111 (6.8) 3.44 (2.83–4.19)
Androgen use
No 238 (2.5) 280 (2.8) 1.0 (ref)
Yes 15 (2.1) 7 (1.6) 0.69 (0.44–1.07)
aCohorts were matched for sex, age according to the date of birth (matched within 1 year), weight [matched within 5 pounds; reported in kg as
mean (SD)], and steroid use.
bReference group is controls.
cMedian household income by geographic region.
Abbreviations: CI, confidence interval; OR, odds ratio; ref, reference.
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Charlson/Deyo comorbidity score (e.g., ≥2: OR, 1.95; 95% CI,
1.47–2.59, compared with 0), and steroid use ≥3 months
(OR, 1.92; 95% CI, 1.07–3.45) were associated with fractures
in these patients.
In subgroup analyses of men only, it was similarly shown
that patients with thyroid cancer had a higher incidence of
osteoporosis than matched controls (OR, 1.46; 95% CI,
1.26–1.68) and lower incidence of fractures (OR, 0.70;
95% CI, 0.58–0.85). Detailed results of these subgroup ana-
lyses are outlined in supplemental online Tables 6 and 7.
DISCUSSION
The findings of this study provide information regarding the
risk of osteoporosis and fragility fractures in U.S. veterans
with thyroid cancer and the factors associated with these
adverse skeletal events. In this predominantly male popula-
tion, osteoporosis, but not fractures, was more common in
the thyroid cancer cohort compared with age-, sex-, weight-,
Table 4. Subgroup analysis of longitudinal TSH and other




n (%) OR (95% CI)
Sex
Male 539 (6.2) 1.0 (ref)
Female 215 (12.8) 4.24 (3.53–5.10)
Age, yr
<50 70 (3.5) 1.0 (ref)
50–64 300 (6.6) 3.09 (2.34–4.07)
65–74 192 (8.5) 5.66 (4.17–7.67)
75–84 157 (11.6) 9.61 (6.99–13.21)
≥85 35 (18.3) 17.18 (11.12–26.54)
TSHa 1.08 (0.001–125)b 0.93 (0.90–0.97)
Median household
incomec
<$35,000 89 (6.8) 1.0 (ref)
$35,000–$59,999 440 (7.2) 1.09 (0.86–1.38)
≥$60,000 225 (7.7) 1.18 (0.92–1.52)
Charlson/Deyo
comorbidity score
0 385 (6.3) 1.0 (ref)
1 108 (8.4) 1.07 (0.86–1.34)
≥2 261 (8.9) 1.03 (0.87–1.21)
Androgen use
No 710 (7.3) 1.0 (ref)
Yes 44 (6.6) 1.63 (1.18–2.23)
Steroid use
<3 mo 744 (7.7) 1.0 (ref)
≥3 mo 10 (1.6) 0.65 (0.34–1.24)
aTSH was log transformed and analyzed as a continuous, time-varying
covariate for the analysis.
bTSH median and range reported in mIU/L.
cMedian household income by geographic region.
Abbreviations: CI, confidence interval; OR, odds ratio; ref, reference;
TSH, thyroid-stimulating hormone.
Figure 1. Subgroup analysis of U.S. veterans with thyroid cancer
using longitudinal TSH (analyzed as a categorical variable) and
osteoporosis risk (2004–2013).
Abbreviation: TSH, thyroid-stimulating hormone.
Table 5. Subgroup analysis of longitudinal TSH and other
characteristics associated with fractures in patients with
thyroid cancer (2004–2013)
Characteristics Fractures, n(%) OR (95% CI)
Sex
Male 212 (2.4) 1.0 (ref)
Female 41 (2.4) 1.54 (1.07–2.22)
Age, yr
<50 26 (1.3) 1.0 (ref)
50–64 112 (2.5) 1.77 (1.13–2.78)
65–74 50 (2.2) 1.78 (1.07–2.96)
75–84 48 (3.5) 3.28 (1.95–5.50)
≥85 17 (8.9) 9.78 (5.15–18.57)
TSHa 1.08 (0.001–125)b 1.01 (0.96–1.07)
Median household
incomec
<$35,000 31 (2.4) 1.0 (ref)
$35,000–$59,999 158 (2.6) 1.16 (0.79–1.71)
≥$60,000 64 (2.2) 1.01 (0.65–1.55)
Charlson/Deyo
comorbidity score
0 88 (1.4) 1.0 (ref)
1 41 (3.2) 1.66 (1.14–2.41)
≥2 124 (4.2) 1.95 (1.47–2.59)
Androgen use
No 238 (2.5) 1.0 (ref)
Yes 15 (2.2) 1.27 (0.75–2.16)
Steroid use
<3 mo 241 (2.5) 1.0 (ref)
≥3 mo 12 (1.6) 1.92 (1.07–3.45)
aTSH was log transformed and analyzed as a continuous,
time-varying covariate for the analysis.
bTSH median and range reported in mIU/L.
cMedian household income by geographic region.
Abbreviations: CI, confidence interval; OR, odds ratio; ref, reference;
TSH, thyroid-stimulating hormone.
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and steroid use-matched controls, even when controlling
for comorbidities, median household income, and andro-
gen use. Lower TSH, female sex, older age, and androgen
use were associated with risk of osteoporosis in the thy-
roid cancer cohort in longitudinal analysis. However, pri-
mary correlates with osteoporosis were female sex and
older age, both known risk factors [17, 18], whereas the
effect of low TSH in this cohort was small.
Prior studies on the risk of osteoporosis in patients
with thyroid cancer have included only small numbers of
men [1, 6–10]. In the few studies with larger cohorts of men
with thyroid cancer, findings have shown no change in bone
mineral density [1, 8–10]. However, these prior studies were
heterogeneous, were limited by varying degrees of control for
confounding variables, and investigated diverse endpoints in
mainly cross-sectional studies with small sample sizes
(n = 4–33) [1]. Data on fracture risk in patients with thyroid
cancer on thyroid hormone therapy are scarce, and none of
the existing studies focused specifically on men. A more
recent study by Blackburn et al. evaluated aging-related dis-
eases among thyroid cancer survivors (n = 3,706, of which
821 were men) compared with a matched cancer-free cohort
(n = 15,587). They found that osteoporosis, but not fractures,
were increased in patients with thyroid cancer compared with
controls (p < .01). However, this study lacked TSH data [3].
Prior studies attempting to elucidate the relationship
between TSH suppression and osteoporosis and fractures
in patients with thyroid cancer yielded controversial results
[1, 19, 20]. Although theories for how TSH suppression may
lead to bone loss include a possible direct effect on bone for-
mation and bone resorption mediated by the TSH receptor
on osteoblast and osteoclast precursors [21–23], it has previ-
ously not been clear if risks of TSH suppression pertained
equally to men as to women. Additionally, data on how the
severity and duration of low TSH affects bone health are con-
flicting [20, 24–26]. It is unknown whether findings from
studies on endogenous hyperthyroidism should be extrapo-
lated to exogenous hyperthyroidism, and the duration of per-
sistently low TSH necessary to affect the skeleton remains
unclear. TSH suppression has been shown to be associated
with an increased risk of osteoporosis in the majority,
but not all, of the studies including postmenopausal women
[1, 19, 20]. Wang et al. showed that 5.4% of women with
thyroid cancer treated at a single institution were diagnosed
with postoperative osteoporosis after a median follow-up
of 6.5 years (n = 537). Interestingly, postoperative TSH sup-
pression (TSH ≤0.4 mIU/L) significantly increased the risk of
postoperative osteoporosis among women with low and
intermediate-risk differentiated thyroid cancer by 3.5-fold
without changing risk for recurrence [20]. However, there has
not been strong evidence that TSH suppression leads to
increased risk of osteoporosis in men, because of existing stud-
ies being limited by lack of power [1]. Karner et al. conducted
the only longitudinal study to date in men and showed no
change in bone mineral density in men with thyroid cancer
with suppressed TSH, except for loss of bone mass in the distal
radius (n = 9) [27]. In addition to the small sample size, this
study also lacked a control group. As our study focused on a
large sample of U.S. veterans with thyroid cancer, the majority
of which were male, we provide a unique insight on the role
of TSH suppression therapy on osteoporosis in these patients,
the effect of which appears to be small.
In regard to risk for fractures in patients with thyroid can-
cer, a large population-based Korean study (n = 185,956) that
included men with thyroid cancer (n = 31,922) looked exclu-
sively at fractures and found that patients with thyroid cancer
were more likely to be treated with osteoporosis medication
(hazard ratio [HR], 1.22; 95% CI, 1.18–1.26) compared with a
matched comparison group. In this other study, patients were
matched to controls by age, sex, residence, income, and dis-
ability. The authors also demonstrated a J-shaped dose-
dependent relationship between TSH suppression and fracture
risk, a finding we did not elucidate in our study [28].
Major strengths of our study include the large, national
sample of predominantly male U.S. veterans, the case-control
study design complemented by a longitudinal analysis con-
taining biochemical data (serum TSH values measured at
multiple points in time), the availability of pharmacy prescrip-
tion data, and the long-term follow-up to detect adverse skel-
etal outcomes, such as osteoporosis and fragility fractures. In
addition, osteoporosis in male patients with thyroid cancer is
understudied, and the rich U.S. Department of Veteran’s
Affairs (VA) data set allowed for a subgroup analysis in males.
Our findings are generalizable to veterans across the U.S.,
and potentially to nonveteran, largely male cohorts.
The study also has limitations. First, as is inherent to
large administrative databases, there may be coding errors
for some diagnoses and procedures. However, a previous
study showed that manual chart review of randomly selected
patients yielded a positive predictive value of 82% and 84%
for using ICD-9 codes in the VA system to diagnose low bone
mineral density and fragility fractures, respectively [29]. Sec-
ond, confounding variables may be missing or poorly mea-
sured (e.g. alcohol, smoking). Third, reflective of the fact that
this is a real-world setting, it is possible that veterans may
have also received patient care in non-VA systems, and out-
comes may not have been captured. In the real-world set-
ting, physicians are expected to update medical records
appropriately with true diagnoses, so we assume that if a
diagnosis of osteoporosis exists in the records, then a bone
density scan must have been performed previously to sub-
stantiate this. Furthermore, as we expect that patients diag-
nosed with osteoporosis would have had at least one bone
mineral density scan, these two variables are highly corre-
lated, and adding the number of bone mineral density scans
as a covariate to our model is unlikely to yield further mean-
ingful information. Additionally, even though the VHA pro-
vides an incentive for eligible veterans to obtain all of their
prescriptions within the VA system at a low cost, it is possible
that some veterans used outside health care systems for phar-
macologic care. Next, serum TSH may have been checked
more frequently in certain patients versus others. To accom-
modate for this difference, we used generalized linear mixed-
effects regression models in which TSH was considered a
time-varying covariate in our longitudinal analyses. Although
we matched for age, sex, weight, and steroid use, additional
covariates were not balanced between the two cohorts and
may have contributed to the disparate rate of osteoporosis.
The higher number of bone density scans performed in
the thyroid cancer cohort likely indicates screening bias,
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perhaps owing to physician concern about the potential
effects of iatrogenic thyrotoxicosis on bone. These findings
have clinical implications. Patients with thyroid cancer may
be subject to increased screening with bone density scans
irrespective of their overall risk for osteoporosis and frac-
tures, leading to unnecessary increased health care use and
increased costs. Also, physicians may be overestimating the
effect of thyroid cancer treatments on bone health. In con-
trast, osteoporosis may be underdiagnosed in the population
at large without thyroid cancer despite the presence of other
risk factors, which in turn may lead to undertreatment and
subsequent fractures. Further research is needed to ade-
quately explain the lower incidence of fractures in patients
with thyroid cancer compared with the general population.
CONCLUSION
Our study offers unique insight on the risk for osteoporosis
and fractures in a largely male thyroid cancer cohort. The
higher incidence of osteoporosis seen in patients with thy-
roid cancer appears to be multifactorial, with iatrogenic
hyperthyroidism playing only a small role. Physicians who
participate in the long-term care of patients with thyroid
cancer should take into consideration a variety of factors in
addition to TSH level when considering risk for osteoporosis.
These risk factors should include medications and other con-
ditions adversely affecting bone health and, importantly, the
patient’s age and sex.
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For Further Reading:
Maria Papaleontiou, Sarah T. Hawley, Megan R. Haymart. Effect of Thyrotropin Suppression Therapy on Bone in
Thyroid Cancer Patients. The Oncologist 2016;21:165–171.
Implications for Practice:
The standard treatment for thyroid cancer includes total thyroidectomy with or without radioactive iodine ablation,
often followed by thyrotropin suppression therapy. Despite current guidelines, controversy exists regarding the degree
and duration of thyrotropin suppression therapy, and discordant results have been reported on its adverse effects on
bone. The present review provides physicians with existing data on the skeletal effects of thyrotropin suppression
therapy, highlighting the need for further research to identify the groups at risk of adverse skeletal effects. This
knowledge will aid in developing tailored thyroid cancer treatment.
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